The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

Daniel Kaplan

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

Oakvile, Canada

Waterloo, Canada

Dayton, OH

Ontario, CA

Psoriasis Treatment Center of Central New Jersey

Bay City, MI

Greensboro - Cardiology

Indianapolis, IN

Norfolk, VA

Forest Hills Dermatology Group

Plainfield, IN

Charlotte, NC

Rolling Meadows, IL

Johnston, RI

Brighton, MA

Quincy, MA

Marietta, GA

Charleston, SC

Anniston, AL

Jacksonville, FL

Minnesota Clinical Study Center

North Little Rock

Saint Joseph, MO

Rogers, AR

Hot Springs, AR

KMC Research Center

Fort Smith, AR

Tampa, FL

Tulsa, OK

Margate, FL

Hollywood, FL

Miami Lakes, FL

Hialeah, FL

Miami, FL

Miami,, FL

Coral Gables, FL

Dallas, TX

Arlington, TX

Clear Lake-Webster, TX

Texas Medical Center

Bellaire, TX

Pflugerville, TX

San Antonio, Texas

San Antonio, TX

Veracruz, Mexico

Calgary, Canada

Scottsdale, AZ

Spokane, WA

Poway, CA

San Diego, CA

Encinitas, CA

Laguna Niguel, CA

Inglewood, CA

Los Angeles, CA

Canoga Park, California

Portland, OR

Sacramento, CA

Lafayette, CA

Fremont, CA

Hautzentrum im Jahrhunderthaus

Hamburg, Germany

Clinical Trial Center

Darlinghurst Clinic & Day Surgery - Research & Clinical Trials Unit

Sydney, Australia

Kogarah, Australia

Carlton, Australia

 Fremantle, Australia

Lilly

This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 4-arm study in adult participants with moderate to severe AD who are inadequately controlled with topical therapies or for whom such topical therapies are inadvisable and who are candidates for systemic therapy.

Participants will be randomized to receive SAR444656 dose 1, dose 2, dose 3 or matching placebo.

Participants who meet inclusion/exclusion criteria will be stratified for randomization by severity of AD (moderate \[baseline EASI score \<22\] versus severe \[baseline EASI score ≥22\]).

The total duration of study is approximately 24 weeks, including 1 to 4 weeks for screening, 16 weeks for double-blind study treatment and 4 weeks for follow-up.

Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

Boynton Beach, FL

Weston, FL

Sanofi

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib Dose A or dupilumab Dose A. Based on the participants response to upadacitinib Dose A, they may have their dose increased to upadacitinib Dose B after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult participants ages 18 to 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 94 sites worldwide.

The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Plymouth Meeting, PA

West Lafayette, Indiana

Dawsonville, GA

Lincoln, NE

Coral Springs - Oncology

Plano, TX

Cypress, TX

Austin, TX

San Juan, PR

Boise, ID

 Thousand Oaks, CA

AbbVie

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Bexley, OH

Towson, MD

Hamilton, Canada

Mississauga, Canada

Derm Center

Troy, MI

Toronto, Canada

Ontario, Canada

Richmond Hill, Canada

Newmarket, Canada

Internal Medicine Glennan Center for Geriatrics and Gerontology

New York, NY

Jose Garcia, Coordinator

Ottawa, Canada

Clinical Operations Department

SLUCare Academic Pavilion - Endocrinology Division Research

Dermatology and Skin Cancer Center Leawood

Boca Raton, FL

McGovern Medical School - ACTAT - Research Department

Rapid City, SD

Saskatoon, Canada

Albuquerque, NM

 Edmonton, Canada

Research Center

Las Vegas, NV

Kelowna, Canada

Reno - Moana Lane Location

Long Beach, CA

Bakersfield, CA

Northridge, CA

Santa Monica, CA

Clinical Research Institute of Southern Oregon (CRISOR)

Dublin, CA

Maldegem, Belgium

Clinical Research Unit

Remscheid, Germany

Hannover, Germany

Haematology Department

Tartu, Estonia

Szolnok, Hungary

Santiago, Chile

Amgen

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Brown Dermatology Research - Clinical Trials Unit

Clearwater, FL

Sunrise, FL

St. Johns, NL

Edmonton, AB

Phoenix, AZ

Gothia Forum - Clinical Trial Center

This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.

A Study Evaluating APG777 in Atopic Dermatitis

Apogee Therapeutics, Inc.

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Galderma

Find clinical trials for Eczema in Pittsburgh, PA

Related conditions:

Eczema trials near Pittsburgh, PA, USA:

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis (AD)

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis (ADVANTA)

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up)

A Study Evaluating APG777 in Atopic Dermatitis

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in .css-epvm6{white-space:nowrap;}Pittsburgh, PA

Related conditions:

Eczema trials near Pittsburgh, PA, USA:

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis (AD)

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis (ADVANTA)

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up)

A Study Evaluating APG777 in Atopic Dermatitis

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in Pittsburgh, PA